Steven Powell

19.6k total citations · 2 hit papers
91 papers, 3.6k citations indexed

About

Steven Powell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Steven Powell has authored 91 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Steven Powell's work include Cancer Immunotherapy and Biomarkers (34 papers), Lung Cancer Treatments and Mutations (27 papers) and Lung Cancer Research Studies (13 papers). Steven Powell is often cited by papers focused on Cancer Immunotherapy and Biomarkers (34 papers), Lung Cancer Treatments and Mutations (27 papers) and Lung Cancer Research Studies (13 papers). Steven Powell collaborates with scholars based in United States, Spain and Italy. Steven Powell's co-authors include Shirish M. Gadgeel, Corey J. Langer, Mark M. Awad, Amita Patnaik, Lecia V. Sequist, Hossein Borghaei, Matthew A. Gubens, James Stevenson, Shadia I. Jalal and Leena Gandhi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Steven Powell

86 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

2016 1.1k citations Corey J. Langer, Shirish M. Gadgeel et al. profile →
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Powell United States	21	2.6k	1.6k	608	575	426	91	3.6k
Shaodong Hong China	28	2.9k 1.1×	1.8k 1.2×	542 0.9×	463 0.8×	619 1.5×	128	3.9k
Kathryn A. Gold United States	29	2.1k 0.8×	1.8k 1.2×	297 0.5×	338 0.6×	922 2.2×	99	3.5k
Anne O’Neill United States	30	1.8k 0.7×	822 0.5×	620 1.0×	587 1.0×	505 1.2×	89	3.5k
Jill Gilbert United States	33	2.1k 0.8×	1.2k 0.8×	633 1.0×	1.1k 2.0×	1.1k 2.5×	91	4.5k
Xiuyu Cai China	24	1.0k 0.4×	659 0.4×	318 0.5×	282 0.5×	438 1.0×	99	2.1k
Hai-Qiang Mai China	29	1.3k 0.5×	627 0.4×	310 0.5×	922 1.6×	753 1.8×	74	2.9k
Hendrik A. Wolff Germany	31	1.2k 0.5×	835 0.5×	115 0.2×	828 1.4×	632 1.5×	106	2.6k
Madeleine Kane United States	25	1.4k 0.5×	1.6k 1.0×	122 0.2×	751 1.3×	854 2.0×	59	4.0k
Hans Christiansen Germany	36	1.0k 0.4×	1.7k 1.1×	116 0.2×	1.1k 1.9×	581 1.4×	203	3.9k
Takaaki Arigami Japan	35	1.9k 0.7×	1.5k 0.9×	596 1.0×	935 1.6×	744 1.7×	188	3.5k

Countries citing papers authored by Steven Powell

Since Specialization

Citations

This map shows the geographic impact of Steven Powell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Powell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Powell more than expected).

Fields of papers citing papers by Steven Powell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Powell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Powell. The network helps show where Steven Powell may publish in the future.

Co-authorship network of co-authors of Steven Powell

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Powell. A scholar is included among the top collaborators of Steven Powell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Powell. Steven Powell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrington, Kevin J., Stéphane Champiat, Joshua Brody, et al.. (2025). Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(16). 3400–3411. 10 indexed citations

Mahalingam, Devalingam, Anwaar Saeed, Steven Powell, et al.. (2025). Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer. ESMO Open. 10(6). 105122–105122. 2 indexed citations

Hernandez, Sharia, Rossana Lazcano, Alejandra G. Serrano, et al.. (2022). Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler. Frontiers in Oncology. 12. 890410–890410. 69 indexed citations

Powell, Steven, et al.. (2021). The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications. Cancers. 13(20). 5206–5206. 55 indexed citations

Awad, Mark M., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2021). OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. 16(1). S8–S8. 1 indexed citations

Bleeker, Jonathan, Christopher Sumey, Steven Powell, et al.. (2020). Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program. Surgery Open Science. 2(4). 25–31. 1 indexed citations

Gadgeel, Shirish M., Marina Chiara Garassino, Emilio Esteban, et al.. (2019). O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology. 14(11). S1153–S1153. 3 indexed citations

Cohen, Ezra E.W., Michael J. Pishvaian, Dale R. Shepard, et al.. (2019). A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 7(1). 342–342. 45 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129. 169 indexed citations

10.

Rodríguez‐Abreu, Delvys, M.C. Garassino, Emilio Esteban, et al.. (2018). KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. Annals of Oncology. 29. ix164–ix164. 4 indexed citations

11.

Garassino, Marina Chiara, Delvys Rodríguez‐Abreu, S. Gadgeel, et al.. (2018). PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. Journal of Thoracic Oncology. 13(9). S155–S155. 1 indexed citations

12.

Gubens, Matthew A., Lecia V. Sequist, James Stevenson, et al.. (2018). Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 130. 59–66. 74 indexed citations

13.

Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →

14.

Haddad, Robert I., Tanguy Y. Seiwert, David G. Pfister, et al.. (2016). Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055. Annals of Oncology. 27. vi330–vi330. 11 indexed citations

15.

Langer, Corey J., Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, et al.. (2016). Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Annals of Oncology. 27. vi582–vi582. 8 indexed citations

16.

Powell, Steven, et al.. (2016). Unresectable Cutaneous Squamous Cell Carcinoma of the Forehead With MLH1 Mutation Showing Dramatic Response to Programmed Cell Death Protein 1 Inhibitor Therapy. PubMed. 1(1). 26–29. 16 indexed citations

17.

Powell, Steven, et al.. (2013). Synchronous and metachronous malignancies: analysis of the Minneapolis Veterans Affairs (VA) tumor registry. Cancer Causes & Control. 24(8). 1565–1573. 14 indexed citations

18.

Ahmed, Imdad, et al.. (2009). Cryptococcal meningitis presenting with recurrent syncope in a patient with chronic lymphoid leukemia: a case report. Cases Journal. 2(1). 103–103. 3 indexed citations

19.

Jin, Lee‐Way, et al.. (2005). Polarimetric imaging of amyloid. Micron. 37(4). 324–338. 19 indexed citations

20.

Powell, Steven, et al.. (1978). Psychoactive drug interactions.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 39(9). 720–9. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact